Strategic partnerships Recursion leverages a massive proprietary biological and chemical dataset and operates one of the world’s most powerful computational platforms, presenting a strong opportunity to partner on data-driven drug discovery programs, AI-driven target validation, and scale-up of computational biology pipelines with external biotech or pharma entities.

Clinical stage leverage As a clinical stage TechBio company with ongoing Q2 2026 updates and inducement equity activity, there is potential to engage in collaborative development deals, milestone-based partnerships, and potential licensing agreements around Recursion OS capabilities to accelerate late-stage programs.

Global footprint With offices in Salt Lake City, Montréal, New York, London, and the Oxford area, there are regional access points for regional partnerships, clinical collaborations, and co-development initiatives tailored to local biotech ecosystems and funding landscapes.

Talent and incentives Recent inducement RSU grants to new employees indicate ongoing talent expansion, suggesting openness to partner-level talent exchanges, joint clinical advisory arrangements, and collaboration intensification with researchers and engineers to advance shared R&D goals.

Financial momentum A revenue range of 25–50 million alongside substantial funding and investor activity signals capacity for co-development funding, strategic investments, and joint ventures where Recursion’s data assets and platform deliver differentiating value.